Topical pharmacotherapy for skin cancer: Part I. Pharmacology

Journal of the American Academy of Dermatology

Volumn 70, Issue 6, 2014, Pages 965.e1-965.e12

  Micali, Giuseppe ^a   Lacarrubba, Francesco ^a   Nasca, Maria Rita ^a   Schwartz, Robert A ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

5 fluorouracil; betulinic acid; diclofenac; dobesilate; imiquimod; ingenol mebutate; piroxicam; resiquimod; retinoids; skin cancer

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; BETULIC ACID; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; PIROXICAM; RESIQUIMOD; RETINOID; ANTINEOPLASTIC AGENT;

ARTICLE; BLISTER; CONJUNCTIVITIS; DRY SKIN; ECTROPION; EROSION; ERYTHEMA; EYE IRRITATION; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; KERATITIS; MEDICAL EDUCATION; PRIORITY JOURNAL; PRURITUS; PUSTULE; SIDE EFFECT; SKIN BURNING SENSATION; SKIN CANCER; SKIN EXFOLIATION; SKIN NECROSIS; SKIN TUMOR; SWELLING; CARCINOMA, BASAL CELL; FEMALE; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, TOPICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84901005686     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.12.045     Document Type: Review

References (65)

1. E. Klein, H. Milgrom, F. Helm, J. Ambrus, H.L. Traenkle, and H.L. Stoll Tumors of the skin: effects of local use of cytostatic agents Skin (Los Angeles) 1 1962 81 87
2. E. Klein, H.L. Stoll, E. Miller, H. Milgrom, F. Helm, and G. Burgess The effects of 5-fluorouracil (5-FU) ointment in the treatment of neoplastic dermatoses Dermatologica 140 Suppl 1 1970 21 33
3. E. Klein, H.L. Stoll Jr., H. Milgrom, F. Helm, and M.J. Walker Tumors of the skin. XII. Topical 5-fluorouracil for epidermal neoplasms J Surg Oncol 3 1971 331 349
4. S.T. McGillis, and H. Fein Topical treatment strategies for non-melanoma skin cancer and precursor lesions Semin Cutan Med Surg 23 2004 174 183
5. J.M. Weinberg Topical therapy for actinic keratoses: current and evolving therapies Rev Recent Clin Trials 1 2006 53 60
6. D.A. Askew, S.M. Mickan, H.P. Soyer, and D. Wilkinson Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials Int J Dermatol 48 2009 453 463
7. G. Micali, F. Lacarrubba, F. Dinotta, D. Massimino, and M.R. Nasca Treating skin cancer with topical cream Expert Opin Pharmacother 11 2010 1515 1527
8. T. Desai, C.L. Chen, A. Desai, and W. Kirby Basic pharmacology of topical imiquimod, 5-fluorouracil, and diclofenac for the dermatologic surgeon Dermatol Surg 38 2012 97 103
9. D. Nashan, F. Meiss, and M. Müller Therapeutic strategies for actinic keratoses - a systematic review Eur J Dermatol 23 2013 14 32
10. E. Stockfleth, H. Kerl, T. Zwingers, and C. Willers Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results Br J Dermatol 165 2011 1101 1108
11. H. Bargman, and J. Hochman Topical treatment of Bowen's disease with 5-fluorouracil J Cutan Med Surg 7 2003 101 105
12. A. Salim, J.A. Leman, J.H. McColl, R. Chapman, and C.A. Morton Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease Br J Dermatol 148 2003 539 543
13. D. Hecker, S.M. Hacker, F.A. Ramos-Caro, and F.P. Flowers Temporary ectropion due to topical fluorouracil Cutis 53 1994 137.e8
14. D. Nikkhah, A. Abood, and D. Watt Cicatricial ectropion: a complication of topical 5-fluorouracil J Plast Reconstr Aesthet Surg 65 2012 e9 10
15. M.R. Johnson, A. Hageboutros, K. Wang, L. High, J.B. Smith, and R.B. Diasio Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil Clin Cancer Res 5 1999 2006 2011
16. K. Loven, L. Stein, K. Furst, and S. Levy Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis Clin Ther 24 2002 990 1000
17. F. Lacarrubba, M.R. Nasca, and G. Micali Advances in the use of topical imiquimod to treat dermatologic disorders Ther Clin Risk Manag 4 2008 87 97
18. G.K. Patel, R. Goodwin, M. Chawla, P. Laidler, P.E. Price, and A.Y. Finlay et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double blind, placebo-controlled trial J Am Acad Dermatol 54 2006 1025 1032
19. M. Schön, and M.P. Schön The antitumoral mode of action of imiquimod and other imidazoquinolines Curr Med Chem 14 2007 681 687
20. V.W. Li, W.W. Li, K.E. Talcott, and A.W. Zhai Imiquimod as an antiangiogenic agent J Drugs Dermatol 4 2005 708 717
21. B. Berman, T. Sullivan, T. De Araujo, and M. Nadji Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle Br J Dermatol 149 Suppl 66 2003 59 61
22. M. Akkilic-Materna, C. Massone, and P. Komericki Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer Acta Derm Venereol 91 2011 432 435
23. F. Lacarrubba, M.C. Potenza, S. Gurgone, and G. Micali Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review J Dermatolog Treat 22 2011 353 358
24. G. Micali, F. Lacarrubba, M.R. Nasca, and R. De Pasquale The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome Clin Exp Dermatol 28 S1 2003 19 23
25. T. Neubert, and P. Lehmann Bowen's disease - a review of newer treatment options Ther Clin Risk Manag 4 2008 1085 1095
26. G. Micali, M.R. Nasca, and R. De Pasquale Erythroplasia of Queyrat treated with imiquimod 5% cream J Am Acad Dermatol 55 2006 901 903
27. D. Gil-Bistes, N. Kluger, V. Rigau, and B. Guillot Successful treatment of recurrent extramammary Paget's disease of the penis and scrotum with imiquimod 5% cream Presse Med 40 2011 1205 1206
28. G. Micali, F. Lacarrubba, B. Nardone, and M.R. Nasca Videodermatoscopy of lentigo maligna treated with imiquimod J Drugs Dermatol 7 2008 1077 1080
29. A. Steinmann, J.O. Funk, G. Schuler, and P. von den Driesch Topical imiquimod treatment of a cutaneous melanoma metastasis J Am Acad Dermatol 43 2000 555 556
30. C. Caperton, and B. Berman Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses Clin Cosmet Investig Dermatol 4 2011 35 40
31. K. Kaidbey, M. Owens, M. Liberda, and M. Smith Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation Toxicology 178 2002 175 182
32. S.K. Attili, S.H. Ibbotson, and C. Fleming Role of non-surgical therapies in the management of periocular basal cell carcinoma and squamous intra-epidermal carcinoma: a case series and review of the literature Photodermatol Photoimmunol Photomed 28 2012 68 79
33. I. Shoimer, N. Rosen, and C. Muhn Current management of actinic keratoses Skin Therapy Lett 15 2010 5 7
34. R. Strohal, H. Kerl, and L. Schuster Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists J Drugs Dermatol 11 2012 574 578
35. H. Zhan, and H. Zheng The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention Am J Clin Dermatol 8 2007 195 200
36. C.G. Nelson Diclofenac gel in the treatment of actinic keratoses Ther Clin Risk Manag 7 2011 207 211
37. A. Maltusch, J. Röwert-Huber, C. Matthies, S. Lange-Asschenfeldt, and E. Stockfleth Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis J Dtsch Dermatol Ges 9 2011 1011 1017
38. H.F. Merk Topical diclofenac in the treatment of actinic keratoses Int J Dermatol 46 2007 12 18
39. A.K. Gupta, M. Paquet, E. Villanueva, and W. Brintnell Interventions for actinic keratoses Cochrane Database Syst Rev 12 2012 CD004415
40. S.A. Dawe, J.R. Salisbury, and E. Higgins Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel Clin Exp Dermatol 30 2005 712 713
41. M. Lebwohl, S. Shumack, L.S. Gold, A. Melgaard, T. Larsson, and S.K. Tyring Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses JAMA Dermatol 149 2013 666 670
42. M. Lebwohl, N. Swanson, L.L. Anderson, A. Melgaard, Z. Xu, and B. Berman Ingenol mebutate gel for actinic keratosis N Engl J Med 366 2012 1010 1019
43. R.H. Rosen, A.K. Gupta, and S.K. Tyring Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response J Am Acad Dermatol 66 2012 486 493
44. S. Amini, M.H. Viera, W. Valins, and B. Berman Nonsurgical innovations in the treatment of nonmelanoma skin cancer J Clin Aesthet Dermatol 3 2010 20 34
45. R. Fallen, and M. Gooderham Ingenol mebutate: an introduction Skin Therapy Lett 17 2012 1 3
46. G. Siller, R. Rosen, M. Freeman, P. Welburn, J. Katsamas, and S.M. Ogbourne PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial Australas J Dermatol 51 2010 99 105
47. G. Martin, and N. Swanson Clinical findings using ingenol mebutate gel to treat actinic keratoses J Am Acad Dermatol 68 1 Suppl 1 2013 S39 S48
48. B. Berman New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel Clin Cosmet Investig Dermatol 5 2012 111 122
49. S. Mukherjee, A. Date, V. Patravale, H.C. Korting, A. Roeder, and G. Weindl Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety Clin Interv Aging 1 2006 327 348
50. S. Lee, D. Selva, S.C. Huilgol, R.A. Goldberg, and I. Leibovitch Pharmacological treatments for basal cell carcinoma Drugs 67 2007 915 934
51. P.L. So, M.A. Fujimoto, and E.H. Epstein Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis Mol Cancer Ther 7 2008 1275 1284
52. M. Alirezai, P. Dupuy, P. Amblard, B. Kalis, P. Souteyrand, and A. Frappaz et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses J Am Acad Dermatol 30 1994 447 451
53. S. Kang, M.T. Goldfarb, J.S. Weiss, R.D. Metz, T.A. Hamilton, and J.J. Voorhees et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial J Am Acad Dermatol 49 2003 83 90
54. K. Peris, M.C. Fargnoli, and S. Chimenti Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma N Engl J Med 341 1999 1767 1768
55. S. Chimenti, A.M. Carrozzo, L. Citarella, C. De Felice, and K. Peris Treatment of lentigo maligna with tazarotene 0.1% gel J Am Acad Dermatol 50 2004 101 103
56. H.B. Slade, B. Shroot, S.R. Feldman, D.I. Cargill, and J. Stanfield Reappraising the phototoxicity of tretinoin: a report of four controlled clinical trials Photodermatol Photoimmunol Photomed 25 2009 146 152
57. R.M. Szeimies, J. Bichel, J.P. Ortonne, E. Stockfleth, J. Lee, and T.C. Meng A phase II dose-ranging study of topical resiquimod to treat actinic keratosis Br J Dermatol 159 2008 205 210
58. T. Meyer, C. Surber, L.E. French, and E. Stockfleth Resiquimod, a topical drug for viral skin lesions and skin cancer Expert Opin Investig Drugs 22 2013 149 159
59. E. Campione, L. Diluvio, E.J. Paternò, and S. Chimenti Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score Am J Clin Dermatol 11 2010 45 50
60. R.V. Patel, A. Frankel, and G. Goldenberg An update on nonmelanoma skin cancer J Clin Aesthet Dermatol 4 2011 20 27
61. P. Cuevas, and J.M. Arrazola Treatment of basal cell carcinoma with dobesilate J Am Acad Dermatol 53 2005 526 527
62. P. Cuevas Sánchez, W. Espinoza, C. Pérez, J. Angulo, and G. Giménez-Gallego Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label study Eur J Med Res 16 2011 67 70
63. P. Cuevas, J. Angulo, A. Cuevas-Bourdier, I. Salgüero, and G. Giménez-Gallego Treatment of infiltrative basal cell carcinomas by inhibiting the fibroblast growth factor (FGF)-signal transducer and activator of transcription (STAT)-3 signalling pathways J Cancer Sci Ther 2011 Available at: http://dx.doi.org/10.4172/1948-5956.S3-003
64. C.A. Dehelean, C. Soica, I. Ledeţi, M. Aluaş, I. Zupko, and G Luşcan A et al. Study of the betulin enriched birch bark extracts effects on human carcinoma cells and ear inflammation Chem Cent J 6 2012 137
65. C. Huyke, J. Reuter, M. Rödig, A. Kersten, M. Laszczyk, and A. Scheffler et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study J Dtsch Dermatol Ges 7 2009 128 133